18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
Article Details
- CitationCopy to clipboard
Liao GJ, Clark AS, Schubert EK, Mankoff DA
18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.
J Nucl Med. 2016 Aug;57(8):1269-75. doi: 10.2967/jnumed.116.175596. Epub 2016 Jun 15.
- PubMed ID
- 27307345 [ View in PubMed]
- Abstract
Estrogen receptor (ER) expression in breast cancer is associated with a more favorable prognosis and is necessary for a response to endocrine therapies. Traditionally, ER expression is assessed by in vitro assays on biopsied tumor tissue. However, recent advances have allowed in vivo evaluation of ER expression with (18)F-fluoroestradiol ((18)F-FES) PET. Clinical studies have demonstrated the use of (18)F-FES PET as a method for quantifying in vivo ER expression and have explored its potential as a predictive assay and method of assessing in vivo pharmacodynamic response to endocrine therapy. This review outlines the biology and pharmacokinetics of (18)F-FES, highlights the current experience with (18)F-FES in patient studies on breast cancer and other diseases, and discusses potential clinical applications and the possible future clinical use of (18)F-FES PET.
DrugBank Data that Cites this Article
- Drugs
- Drug Carriers
Drug Carrier Kind Organism Pharmacological Action Actions Fluoroestradiol F-18 Serum albumin Protein Humans UnknownBinderDetails Fluoroestradiol F-18 Sex hormone-binding globulin Protein Humans UnknownBinderDetails